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Background: The drug-eluting stents (DESs) in clinical use are associated with late stent thrombosis and late catch-up, probably owing to delayed 
healing and local inflammatory reactions to the polymer carrier. We compared the long-term safety and efficacy of the newly developed DES Nobori, 
which is coated with the bioabsorbable polymer polylactic acid (PLA) and the anti-proliferative agent Biolimus A9, to those of the Cypher and bare-
metal stent (BMS) in porcine coronary arteries.
Methods: Overlapping Nobori, Cypher, and BMS were implanted into normal porcine coronary arteries (N=33) and examined 2 and 4 weeks later 
by scanning electron microscopy (SEM) or histopathology for endothelialization and vascular healing. Another 18 animals received a single Cypher or 
Nobori stent, and specimens obtained from proximal, middle, and distal regions of the treated segments were examined histopathologically 3, 9, and 
15 months (M) later. A BMS group (N=3) was also examined at 9 M, as a control.
Results: At 4 weeks post-implantation, endothelial coverage was significantly greater for the Nobori than the Cypher (87.8 ± 3.7% vs. 66.4 ± 3.2%, 
p<0.05), and white blood cell adhesion was lower. From partial degradation (3 and 9 M) to disappearance (15 M) of polymer, Nobori specimens 
showed remarkable better healing (identical to BMS) than Cypher ones. Specimens of Nobor implanted arteries showed markedly lower scores for 
inflammation (range 0.00-0.28 vs. 0.47-1.56) and injury (0.42-1.11 vs. 0.52-2.00) compared with the Cypher. The area percent stenosis was also 
well maintained (consistently 40-50%) in the Nobori for up to 15 M. In contrast, progressive stenosis (up to 70%) was observed over the 9-15 M 
period in Cypher specimens, accompanied by circumferential granuloma and severe inflammation extending into the adventitia.
Conclusions: Compared with Cypher, the Nobori showed better biocompatibility and faster healing, with well-maintained efficacy. These findings 
support the idea that degradation of the polymer in the Nobori stent reduces late untoward effects, i.e., late thrombosis and late restenosis, thus 
improving the long-term safety of DES for clinical use.
